Recently, novel drugs such as SGLT2 inhibitors and non-steroidal selective mineralocorticoid receptor antagonists have been proven to reduce albuminuria and protect the heart and kidneys in patients with diabetic nephropathy (Heerspink et al., 2020; Jongs et al., 2021; Neuen et al., 2024; Wheeler et al., 2021). This evidence concerns the gene SLC5A2 and diabetic kidney disease.